Published in Cancer Weekly, January 9th, 2007
"Ten ASODN targeting MK were designed and synthesized. After transfection with ASODN, cell proliferation was analyzed with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-01-09)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.